JP, give it a rest. Gerald and the BOD have deliv

JP, give it a rest. Gerald and the BOD have delivered on a key milestone with this ODD approval, and with many more to follow with MANF applications, what is not good? Revenue? That goes without saying, and will begin shortly. You are a seasoned investor, and one well acquainted with the biotech world. Revenues are distant milestones for most upstart biotechs with very few exceptions. Do us all a favor and take a break my friend. Wishing you and your family a very warm and blessed Christmas, and a healthy, peaceful and prosperous New Year!